The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma
Open accessAbstract
BACKGROUND: Treatment guidelines recommend the regular use of inhaled corticosteroids for patients with mild persistent asthma. We investigated whether the symptom-driven use of a combination of beclomethasone dipropionate and albuterol (also known as salbutamol) in a single inhaler would be as effective as the regular use of inhaled beclomethasone and superior to the as-needed use of inhaled albuterol. METHODS: We conducted a 6-month, double-blind, double-dummy, randomized, parallel-group trial. After a 4-week run-in, patients with mild asthma were randomly assigned to receive one of four inhaled treatments: placebo twice daily plus 250 microg of beclomethasone and 100 microg of albuterol in a single inhaler as needed (as-needed combination therapy); placebo twice daily plus 100 microg of albuterol as needed (as-needed albuterol therapy); 250 microg of beclomethasone twice daily and 100 microg of albuterol as needed (regular beclomethasone therapy); or 250 microg of beclomethasone and 100 microg of albuterol in a single inhaler twice daily plus 100 microg of albuterol as needed (regular combination therapy). The primary outcome was the morning peak expiratory flow rate. RESULTS: In 455 patients with mild asthma who had a forced expiratory volume in 1 second of 2.96 liters (88.36% of the predicted value), the morning peak expiratory flow rate during the last 2 weeks of the 6-month treatment was higher (P=0.04) and the number of exacerbations during the 6-month treatment was lower (P=0.002) in the as-needed combination therapy group than in the as-needed albuterol therapy group, but the values in the as-needed combination therapy group were not significantly different from those in the groups receiving regular beclomethasone therapy or regular combination therapy. The cumulative dose of inhaled beclomethasone was lower in the as-needed combination therapy group than in the groups receiving regular beclomethasone therapy or regular combination therapy (P<0.001 for both comparisons). CONCLUSIONS: In patients with mild asthma, the symptom-driven use of inhaled beclomethasone (250 microg) and albuterol (100 microg) in a single inhaler is as effective as regular use of inhaled beclomethasone (250 microg twice daily) and is associated with a lower 6-month cumulative dose of the inhaled corticosteroid. (ClinicalTrials.gov number, NCT00382889 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma
Pauwels, R. A., Löfdahl, C.-G., Postma, D. S., Tattersfield, A. E., O'Byrne, P., Barnes, P. J., & Ullman, A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711133372001 · Cited by 1,520
Long-Term Effects of Budesonide or Nedocromil in Children with Asthma
(2000) · New England Journal of Medicine · doi:10.1056/nejm200010123431501 · Cited by 1,365
Low-Dose Inhaled Corticosteroids and the Prevention of Death from Asthma
Suissa, S., Ernst, P., Benayoun, S., Baltzan, M., & Cai, B. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430504 · Cited by 1,100
Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study
Rabe, K., Vermeire, P., Soriano, J., & Maier, W. (2000) · European Respiratory Journal · doi:10.1183/09031936.00.16580200 · Cited by 1,025
Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma
(1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380222 · Cited by 864
Haahtela, T., Järvinen, M., Kava, T., Kiviranta, K., Koskinen, S., Lehtonen, K., Nikander, K., Persson, T., Reinikainen, K., Selroos, O., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250603 · Cited by 785
Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial
Pauwels, R. A., Pedersen, S., Busse, W. W., Tan, W. C., Chen, Y.-Z., Ohlsson, S. V., Ullman, A., Lamm, C. J., & O'Byrne, P. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12891-7 · Cited by 763
Effects of Reducing or Discontinuing Inhaled Budesonide in Patients with Mild Asthma
Haahtela, T., Jarvinen, M., Kava, T., Kiviranta, K., Koskinen, S., Lehtonen, K., Nikander, K., Persson, T., Selroos, O., Sovijarvi, A., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409153311103 · Cited by 743
Low Dose Inhaled Budesonide and Formoterol in Mild Persistent Asthma: The OPTIMA Randomized Trial
O'BYRNE, P. M., BARNES, P. J., RODRIGUEZ-ROISIN, R., RUNNERSTROM, E., SANDSTROM, T., SVENSSON, K., & TATTERSFIELD, A. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.8.2104102 · Cited by 680
Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma
O'Byrne, P. M., Bisgaard, H., Godard, P. P., Pistolesi, M., Palmqvist, M., Zhu, Y., Ekström, T., & Bateman, E. D. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200407-884oc · Cited by 657
Cited by
Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-060st · Cited by 1,918
Papi, A., Brightling, C., Pedersen, S. E., & Reddel, H. K. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33311-1 · Cited by 1,759
Self-citationAfter asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Cloutier, M. M., Baptist, A. P., Blake, K. V., Brooks, E. G., Bryant-Stephens, T., DiMango, E., Dixon, A. E., Elward, K. S., Hartert, T., Krishnan, J. A., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.10.003 · Cited by 854
Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma
O’Byrne, P. M., FitzGerald, J. M., Bateman, E. D., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Ivanov, S., & Reddel, H. K. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715274 · Cited by 645
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02730-2021 · Cited by 537
As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma
Bateman, E. D., Reddel, H. K., O’Byrne, P. M., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Siwek-Posluszna, A., & FitzGerald, J. M. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715275 · Cited by 516
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2205pp · Cited by 512
Martinez, F. D., & Vercelli, D. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61536-6 · Cited by 496
Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma
Beasley, R., Holliday, M., Reddel, H. K., Braithwaite, I., Ebmeier, S., Hancox, R. J., Harrison, T., Houghton, C., Oldfield, K., Papi, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901963 · Cited by 466
Self-citationFanta, C. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804579 · Cited by 400
Reddel, H. K., FitzGerald, J. M., Bateman, E. D., Bacharier, L. B., Becker, A., Brusselle, G., Buhl, R., Cruz, A. A., Fleming, L., Inoue, H., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01046-2019 · Cited by 390
Martinez, F. D., Chinchilli, V. M., Morgan, W. J., Boehmer, S. J., Lemanske, R. F., Mauger, D. T., Strunk, R. C., Szefler, S. J., Zeiger, R. S., Bacharier, L. B., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62145-9 · Cited by 341
Asthma outcomes: Exacerbations
Fuhlbrigge, A., Peden, D., Apter, A. J., Boushey, H. A., Camargo, C. A., Gern, J., Heymann, P. W., Martinez, F. D., Mauger, D., Teague, W. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.12.983 · Cited by 326
Effects of cannabis on pulmonary structure, function and symptoms
Aldington, S., Williams, M., Nowitz, M., Weatherall, M., Pritchard, A., McNaughton, A., Robinson, G., & Beasley, R. (2007) · Thorax · doi:10.1136/thx.2006.077081 · Cited by 316
Lougheed, M. D., Lemiere, C., Ducharme, F. M., Licskai, C., Dell, S. D., Rowe, B. H., FitzGerald, M., Leigh, R., Watson, W., Boulet, L.-P., et al. (2012) · Canadian Respiratory Journal · doi:10.1155/2012/635624 · Cited by 293
Autoantibodies in lung cancer: possibilities for early detection and subsequent cure
Chapman, C. J., Murray, A., McElveen, J. E., Sahin, U., Luxemburger, U., Tureci, O., Wiewrodt, R., Barnes, A. C., & Robertson, J. F. (2008) · Thorax · doi:10.1136/thx.2007.083592 · Cited by 288
Hardy, J., Baggott, C., Fingleton, J., Reddel, H. K., Hancox, R. J., Harwood, M., Corin, A., Sparks, J., Hall, D., Sabbagh, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31948-8 · Cited by 280
Metadata
- Authors
- Papi, A., Canonica, G. W., Maestrelli, P., Paggiaro, P., Olivieri, D., Pozzi, E., Crimi, N., Vignola, A. M., Morelli, P., Nicolini, G., & Fabbri, L. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-05-17
- Volume
- 356
- Issue
- 20
- Pages
- 2040-2052
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2083757777
- Cited by
- 365
- References
- 33
- FWCI
- 16.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.